ProKidney Secures FDA Alignment for Rilparencel Approval
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ProKidney ( (PROK) ) has provided an update.
On July 15, 2025, ProKidney Corp. announced its alignment with the U.S. Food and Drug Administration (FDA) on the accelerated approval pathway for its autologous cellular therapy, rilparencel. The FDA confirmed that the estimated glomerular filtration rate (eGFR) slope is an acceptable surrogate endpoint for accelerated approval in patients with CKD and type 2 diabetes. The ongoing Phase 3 PROACT 1 study will serve both for accelerated and full approval. Nearly half of the patients required for the accelerated approval analysis have been enrolled, with topline data expected in Q2 2027. This regulatory milestone marks significant progress for ProKidney in addressing the unmet needs of patients with advanced CKD and diabetes.
The most recent analyst rating on (PROK) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Underperform.
ProKidney’s stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
ProKidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). Founded in 2015, it specializes in developing autologous cellular therapies, with its lead product candidate rilparencel aimed at preserving kidney function in diabetic patients at high risk of kidney failure.
Average Trading Volume: 12,155,929
Technical Sentiment Signal: Buy
Current Market Cap: $1.33B
For detailed information about PROK stock, go to TipRanks’ Stock Analysis page.
